Sequana Medical NV announced final three-month follow-up data from all three patients in the non-randomized cohort of MOJAVE, the Company's US Phase 1/2a study of DSR 2.0 for treatment of patients with diuretic-resistant heart failure, confirming the dramatic and durable improvement in their diuretic response and virtual elimination of loop diuretic requirements. These final data support DSR's mechanism of action as breaking the virtuous cycle of cardiorenal syndrome. After the last DSR treatment, patients will be followed for a three-month safety follow-up period.

The Company plans to start the randomized phase after receiving US market approval of its alfapump, anticipated by the end of Third Quarter 2024.